Scarica l'app Stockscreener
79.44
3.28%
2.52
Dopo l'orario di chiusura:
79.28
-0.16
-0.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Behavioral Patterns of HALO and Institutional Flows - Stock Traders Daily
Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know - The Globe and Mail
Halozyme Biotech Acquisitions And M&A Plan Weigh On Valuation Case - Sahm
Halozyme Startup Deals Recast Growth Plan And Raise Valuation Questions - Yahoo Finance
Stay Ahead of the Game With Halozyme Therapeutics (HALO) Q4 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance UK
ING Groep NV Acquires New Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Will Halozyme Therapeutics Inc. benefit from rate cutsPortfolio Return Report & Scalable Portfolio Growth Methods - mfd.ru
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results - The Malaysian Reserve
Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth - Finviz
Biotech: Halozyme CEO explains what it looks for in M&A targets - Yahoo Finance
Profund Advisors LLC Trims Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (HALO) to Release Earnings on Tuesday - MarketBeat
Halozyme Expecting Decade of Growth - San Diego Business Journal
New York State Common Retirement Fund Sells 3,399,839 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Renaissance Group LLC Invests $35.11 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Assessing Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance - Sahm
Halozyme Therapeutics stock hits all-time high at 79.99 USD By Investing.com - Investing.com Nigeria
Halozyme Therapeutics (NASDAQ:HALO) Hits New 12-Month HighTime to Buy? - MarketBeat
Halozyme Therapeutics stock hits all-time high at 79.99 USD - Investing.com
A Look At Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance - Yahoo Finance
Halozyme Therapeutics, Inc. $HALO Shares Acquired by Thrivent Financial for Lutherans - MarketBeat
Helen Torley Sells 20,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 10,000 Shares - MarketBeat
Halozyme, Other Hot Medical Plays Lead 22 Stocks Onto Best Stock Lists Like IBD 50, IPO Leaders - Investor's Business Daily
Halozyme’s Drug-Delivery Royalties Are Driving A Rerating Case - Finimize
BI Asset Management Fondsmaeglerselskab A S Sells 155,995 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Hantz Financial Services Inc. Has $7.18 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
2 Under-the-Radar Biotech Stocks Set to Boom in 2026 - AOL.com
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term - Yahoo Finance
Zacks Research Has Positive Outlook of HALO FY2025 Earnings - MarketBeat
Benchmark maintains Buy rating on Halozyme stock amid raised guidance By Investing.com - Investing.com Canada
Q1 EPS Estimate for Halozyme Therapeutics Raised by Analyst - MarketBeat
Halozyme Therapeutics (HALO) Is Up 6.6% After Lifting Guidance And Expanding ENHANZE Beyond Oncology - Sahm
Strs Ohio Sells 25,069 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth - Seeking Alpha
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Uncovering A 8.77% Upside Potential - DirectorsTalk Interviews
(HALO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Why This Stock Of The Day Is Story Of 'Layering And Duration' - Investor's Business Daily
Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report? - Finviz
Merck gains U.S. patent office support in Keytruda dispute - MSN
Halozyme Therapeutics, Inc. $HALO Shares Sold by Y Intercept Hong Kong Ltd - MarketBeat
What Halozyme Therapeutics (HALO)'s Upgraded Revenue Outlook and ENHANZE Acquisitions Strategy Means For Shareholders - Yahoo Finance
Is Halozyme Therapeutics (HALO) Still Attractive After Recent Drug Delivery Partnership-Driven Gains - Sahm
AlphaQuest LLC Acquires 34,011 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Raised to Strong-Buy at Wall Street Zen - MarketBeat
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Setup Watch: Is Halozyme Therapeutics Inc forming a breakout patternDip Buying & AI Optimized Trading Strategy Guides - baoquankhu1.vn
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Q4 EPS Forecast for Halozyme Therapeutics Lifted by Analyst - MarketBeat
Great Lakes Advisors LLC Sells 14,747 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
A Look At Halozyme Therapeutics (HALO) Valuation After Raised Guidance And Drug Delivery Acquisitions - Sahm
H.C. Wainwright Sees Strength in Halozyme Therapeutics' ENHANZE Platform, Reiterates Buy Rating - Finviz
H.C. Wainwright Sees Strength in Halozyme Therapeutics’ ENHANZE Platform, Reiterates Buy Rating - Yahoo Finance
HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance - Finviz
Halozyme stock price target maintained at $58 by Goldman Sachs - Investing.com Canada
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):